Essential Pharma acquires Reminyl from Janssen Pharmaceutica
18 Apr 2024
Phase 2Cell TherapyAcquisitionPhase 1
Preview
Source: Pharmaceutical Technology
Speciality pharmaceutical group Essential Pharma has concluded the acquisition of Reminyl oral capsules from Johnson & Johnson company Janssen Pharmaceutica.
The strategic move enhances Essential Pharma’s portfolio of central nervous system (CNS) medicines and expands its global footprint, particularly in Asia-Pacific.
A cholinesterase inhibitor, Reminyl is an established CNS drug for mild to moderately severe dementia of the Alzheimer type.
Essential Pharma will now hold rights to Reminyl in the European Economic Area, South Korea, Thailand and all other existing markets for this product.
The deal excludes the UK and Ireland, Japan and Latin America.
See Also:
Inaticabtagene autoleucel by Juventas Cell Therapy for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval
Preview
Source: Pharmaceutical Technology
Ulixacaltamide hydrochloride by Praxis Precision Medicines for Essential Tremor: Likelihood of Approval
Preview
Source: Pharmaceutical Technology
The acquisition aligns with Essential Pharma’s focus on CNS, gastroenterology, ophthalmology and rare diseases.
Essential operates in more than 70 countries and is supported by healthcare investment firm Gyrus Capital.
Essential CEO Emma Johnson stated: “Our acquisition of rights to Reminyl in these markets will ensure Alzheimer’s patients and caregivers in those regions have continued access to this vital medicine.
“The acquisition represents a significant and synergistic addition to our concentrated portfolio of CNS products, further expanding our global presence and solidifying our position as a leading speciality pharma group.”
The latest development comes after Essential Pharma acquired clinical-stage pharmaceutical company Renaissance Pharma for an undisclosed sum in April 2024.
Renaissance develops treatments for paediatric rare diseases, with its lead asset, Hu14.18K322A, currently being analysed in a Phase II clinical trial to treat high-risk neuroblastoma.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.